Pirfenidone axunio (previously Pirfenidone AET) Euroopan unioni - suomi - EMA (European Medicines Agency)

pirfenidone axunio (previously pirfenidone aet)

axunio pharma gmbh - pirfenidone - idiopaattinen keuhkofibroosi - immunosuppressantit - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Pirfenidone Viatris Euroopan unioni - suomi - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosuppressantit - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Sorafenib Sandoz 200 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sorafenib sandoz 200 mg tabletti, kalvopäällysteinen

sandoz a/s - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

Sorafenib Mylan 200 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sorafenib mylan 200 mg tabletti, kalvopäällysteinen

mylan ab - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

Sorafenib Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiset aineet - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Silodosin Recordati Euroopan unioni - suomi - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodosiinilla - prostatic hyperplasia - urologicals, alfa-salpaajat - hoitoon oireiden ja eturauhasen hyvänlaatuisen liikakasvun (bph) hoitoon aikuisilla miehillä.